1 June 2022

 Futura Medical plc

("Futura" or the "Company")

Notice of AGM and Availability of Annual Report

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces its Annual General Meeting ("AGM") will be held at 10:00 am on Tuesday 28 June 2022 at the offices of Liberum Capital Limited, Ropemaker Place, 25 Ropemaker Street, London EC2Y 9LY.

Following the easing of coronavirus (COVID-19) restrictions in the UK, the Board has made arrangements to enable shareholders to attend the Annual General Meeting in person. However, in light of the uncertainty as to any further COVID-19 measures that may be put in place by the UK Government and bearing in mind the inherent risk of large gatherings, the Company encourages shareholders to consider submitting their voting instructions in advance by appointing the Chairman of the meeting as their proxy, rather than attending and voting on the day. This will ensure that votes are registered in accordance with shareholders' wishes regardless of any restrictions or disruption around the Annual General Meeting and will also help protect the health and safety of shareholders, directors and other necessary attendees. Depending on the public health situation, we may impose additional procedures or limitations on attendees beyond any described in this Notice of Annual General Meeting.

If you wish to attend the meeting in person, please register your interest, prior to 10:00 a.m. on 24 June 2022 at [email protected].

The Company requests that anyone who has recently tested positive for COVID-19 and/or is showing symptoms, or anyone who lives with somebody who has recently tested positive, does not attend the meeting

Shareholders are asked to cast their vote as follows: (1) casting your proxy vote online by logging on to www.signalshares.com and following the instructions; or (2) in the case of CREST members, by utilising the CREST electronic proxy appointment service; or (3) requesting a hard copy form of proxy directly from the registrars, Link Group. If you choose to attend the Annual General Meeting in person instead of appointing the Chairman of the meeting as proxy as we strongly recommend, you will still be able to vote in person at the Annual General Meeting.

If you are not attending the Annual General Meeting in person, your proxy vote will need to be lodged by 10:00 a.m. on 24 June 2022 as no online voting will take place in-real time during the meeting itself.

The Company will operate an audio dial-in facility to allow shareholders to listen to the business of the meeting: shareholders will need to be confirmed as a shareholder or present a letter of representation before details of how to access this facility are released to them via email the morning of the meeting. You can request access by emailing: [email protected] prior to 10:00 a.m. on 24 June 2022.

This document should be read in conjunction with the Futura Medical plc annual report and accounts. If you are in any doubt as to the action you should take, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent advisor, who, if you are taking advice in the United Kingdom, is authorised pursuant to the Financial Services and Markets Act 2000.

Shareholders will not get an opportunity to vote or ask questions or any other participation during the call.

The situation in relation to COVID-19 is constantly evolving, and the UK Government may change current restrictions or implement further measures relating to the holding of Annual General Meetings during the affected period. We will continue to monitor the situation, and any changes to the Annual General Meeting will be communicated to shareholders before the meeting through our website and, where appropriate, by stock exchange announcement.

Annual Report

Futura's annual report and accounts for the year ended 31 December 2021 (the "Annual Report") is available to shareholders as an electronic communication pursuant to the Companies Act 2006 and is now available at the Company's website www.futuramedical.com, along with the Notice of AGM.

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [email protected]

Tel: +44 (0) 1483 685 670

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings

Tel: +44 (0) 20 3100 2000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: [email protected]

Tel: +44 (0) 203 882 9621

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction ("ED") through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com